Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Fox

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
NPJ Vaccines|November 3, 2022
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stabilityEmily A Voigt, Alana Gerhardt, Derek Hanson, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 26, 2024
Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 modelJoão Azevedo-Silva, Manuela Amorim, Diana Tavares-Valente, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Molecular Therapy. Nucleic Acids|January 2, 2023
Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccinesJohn S Tregoning, David C Stirling, Ziyin Wang, et al.
International Journal of Pharmaceutics|September 4, 2022
Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterizationBrynn M Murphy, John Z Chen, Michael Rolo, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
International Journal of Pharmaceutics|October 7, 2025
A Thermostable nasal spray dried COVID vaccine candidateMaximilian Aisenstat, Kelvin Duong, Christina Renshaw, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2018
A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against ZikaJesse H Erasmus, Amit P Khandhar, Jeff Guderian, et al.
Science (New York, N.Y.)|February 19, 2026
Mucosal vaccination in mice provides protection from diverse respiratory threatsHaibo Zhang, Katharine Floyd, Zhuoqing Fang, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
NPJ Vaccines|November 3, 2022
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stabilityEmily A Voigt, Alana Gerhardt, Derek Hanson, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 26, 2024
Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 modelJoão Azevedo-Silva, Manuela Amorim, Diana Tavares-Valente, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Molecular Therapy. Nucleic Acids|January 2, 2023
Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccinesJohn S Tregoning, David C Stirling, Ziyin Wang, et al.
International Journal of Pharmaceutics|September 4, 2022
Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterizationBrynn M Murphy, John Z Chen, Michael Rolo, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
International Journal of Pharmaceutics|October 7, 2025
A Thermostable nasal spray dried COVID vaccine candidateMaximilian Aisenstat, Kelvin Duong, Christina Renshaw, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2018
A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against ZikaJesse H Erasmus, Amit P Khandhar, Jeff Guderian, et al.
Science (New York, N.Y.)|February 19, 2026
Mucosal vaccination in mice provides protection from diverse respiratory threatsHaibo Zhang, Katharine Floyd, Zhuoqing Fang, et al.
Pageof 15